Patients were randomized @:@:@ to continue natalizumab , to switch to placebo , or to receive alternative immunomodulatory therapy ( other therapies : IM interferon -@ a -LSB- IM IFN -- @a -RSB- , glatiramer acetate -LSB- GA -RSB- , or methylprednisolone -LSB- MP -RSB- ) .